AR126499A1 - COMPOSITIONS OF RNAi DIRECTED TO TARGET GENES ASSOCIATED WITH METABOLIC DISORDERS AND METHODS OF USE THEREOF - Google Patents
COMPOSITIONS OF RNAi DIRECTED TO TARGET GENES ASSOCIATED WITH METABOLIC DISORDERS AND METHODS OF USE THEREOFInfo
- Publication number
- AR126499A1 AR126499A1 ARP220101894A ARP220101894A AR126499A1 AR 126499 A1 AR126499 A1 AR 126499A1 AR P220101894 A ARP220101894 A AR P220101894A AR P220101894 A ARP220101894 A AR P220101894A AR 126499 A1 AR126499 A1 AR 126499A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- target genes
- genes associated
- metabolic disorders
- compositions
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 4
- 108091030071 RNAI Proteins 0.000 title abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
- 102100034135 Activin receptor type-1C Human genes 0.000 abstract 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 abstract 2
- 102000017795 Perilipin-1 Human genes 0.000 abstract 2
- 108010067162 Perilipin-1 Proteins 0.000 abstract 2
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 239000000893 inhibin Substances 0.000 abstract 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Agentes de ARNi, por ejemplo, agentes de ARN de hebra doble (ARNhd), dirigidos a genes diana asociados con trastornos metabólicos, por ejemplo, la subunidad b E de inhibina (INHBE), el receptor tipo 1C de activina A (ACVR1C), perilipina-1 (PLIN1), fosfodiesterasa 3B (PDE3B) o la subunidad b C de inhibina (INHBC). La invención también se relaciona con métodos para usar dichos agentes de ARNi para inhibir la expresión de un gen diana asociado a un trastorno metabólico y con métodos para prevenir y tratar un trastorno metabólico, por ejemplo, el síndrome metabólico.RNAi agents, e.g., double-stranded RNA (dsRNA) agents, targeting target genes associated with metabolic disorders, e.g., inhibin subunit b E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B) or inhibin b C subunit (INHBC). The invention also relates to methods of using such RNAi agents to inhibit the expression of a target gene associated with a metabolic disorder and to methods of preventing and treating a metabolic disorder, for example, metabolic syndrome.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063321799P | 2020-03-21 | 2020-03-21 | |
| US202063323543P | 2020-03-25 | 2020-03-25 | |
| US202063278126P | 2020-11-11 | 2020-11-11 | |
| US202063285143P | 2020-12-02 | 2020-12-02 | |
| US202063287578P | 2020-12-09 | 2020-12-09 | |
| US202163223995P | 2021-07-21 | 2021-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126499A1 true AR126499A1 (en) | 2023-10-18 |
Family
ID=88679297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101894A AR126499A1 (en) | 2020-03-21 | 2022-07-20 | COMPOSITIONS OF RNAi DIRECTED TO TARGET GENES ASSOCIATED WITH METABOLIC DISORDERS AND METHODS OF USE THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126499A1 (en) |
-
2022
- 2022-07-20 AR ARP220101894A patent/AR126499A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020015314A2 (en) | Arni compositions against angiotensinogen (agt) and methods for their use | |
| AR121312A2 (en) | RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THERETO FOR TREATING DISEASES ASSOCIATED WITH TRANSTHYRETIN (TTR) | |
| CL2020002401A1 (en) | Arni compositions of 17 b-hydroxysteroid dehydrogenases type 13 (hsd17b13) and methods of use thereof. | |
| MX2018014152A (en) | Compositions and methods of treating huntington's disease. | |
| PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| MX2016015126A (en) | Angiotensinogen (agt) irna compositions and methods of use thereof. | |
| JO3558B1 (en) | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression | |
| AR100946A1 (en) | COMPOSITIONS AND METHODS TO REGULATE GENE EXPRESSION THROUGH RNA INTERFERENCE | |
| MX2020003961A (en) | Use of p38 inhibitors to reduce expression of dux4. | |
| CO2022006092A2 (en) | Methods and compositions for treating an angiotensinogen (agt)-associated disorder | |
| CO2022016196A2 (en) | Complement factor b (cfb) arni compositions and methods of use thereof | |
| UY37376A (en) | ARNI CONSTRUCTIONS TO INHIBIT EXPRESSION OF ASGR1 AND METHODS FOR USE | |
| MX2020010802A (en) | DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES MODIFIED WITH T<sub>M</sub>-INCREASING NUCLEOTIDES. | |
| CL2022001503A1 (en) | Human chromosome 9 open reading frame 72 (c9orf72) arni agents, compositions | |
| BR112022024420A2 (en) | XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| UY37936A (en) | IRAN AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF THE ASIALOGLICOPROTEIN RECEIVER 1 | |
| AR126499A1 (en) | COMPOSITIONS OF RNAi DIRECTED TO TARGET GENES ASSOCIATED WITH METABOLIC DISORDERS AND METHODS OF USE THEREOF | |
| AR120341A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE | |
| CL2022000539A1 (en) | Compositions and methods for inhibiting lect2 gene expression | |
| CO2024000239A2 (en) | Compositions of target gene RNAi associated with metabolic disorder and their methods of use | |
| CL2022001481A1 (en) | Nucleic acid compositions | |
| BR112022020227A2 (en) | COMPOSITIONS AND METHODS FOR SILENCING THE EXPRESSION OF SCN9A | |
| CO2024001403A2 (en) | Arni compositions and methods to silence angiotensinogen (agt) | |
| AR120712A1 (en) | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF | |
| EA202092726A1 (en) | IRNA-BASED COMPOSITIONS AGAINST ANGIOTENSINOGEN (AGT) AND METHODS OF THEIR APPLICATION |